IAI Announces Medical Assist ELECYLINDER Series

 

IAI (Intelligent Actuator Incorporated) would like to introduce their ELECYLINDER® electric actuator series. The main features are easy operation, AVD (acceleration/speed/deceleration) that can be adjusted individually, and high performance.

Due to its stable quality, it is ideal for the manufacturing industry of medical products where product accuracy is required.

Here is an example of how the smooth operation of ELECYLINDER® improved a packaging application. A conventional air cylinder was used to move a package containing bottles of liquid chemicals between conveyors (vertically connected). When moving at a right angle, the speed at which the product was pushed out was not constant, and the impact caused the package to fall, the liquid in the bottle to deform, or foam during movement.

ELECYLINDER® makes it easy to adjust and control AVD (A: Acceleration, V: Speed, D: Deceleration), allowing packages to move smoothly between conveyors positioned at right angles without affecting internal products. In addition, ELECYLINDER® has a wide range of products available for many types of applications.

“IAI is proud to be at the forefront of technology that supports the medical community in the fight against disease and future health crises,” said Kaz Haruna, National Sales Manager at IAI America.

IAI is actively assisting the medical community by providing Cartesian and SCARA robots for infectious disease testing, molecular diagnostics, tissue and blood sampling, genomic research, cancer research, pharmaceuticals, and medical device production. It is IAI’s hope that our ELECYLINDER® Series will help the medical/pharmaceutical industries move ahead with advanced innovation.

About IAI

Founded in Shimizu, Japan in 1976, Intelligent Actuator Incorporated (IAI) has over forty years of experience in the design and manufacture of customized medical and industrial robotics. Built on “Quality and Innovation,” IAI is a leader in the research and development of advanced energy efficient and affordable Cartesian, SCARA, and Tabletop robots. From entry-level to high-speed models, IAI provides complete programmable systems and components to fulfill any and all of your medical testing and industrial production needs.

★ USA Headquarters & Western Region
2690 West 237 Street, Torrance, CA 90505
(310) 891-6015

★ Midwest Branch Office
110 East State Parkway, Schaumburg, IL 60173
(847) 908-1400

★ Southern Branch Office
1220 Kennestone Circle, Suite 108, Marietta, GA 30066
(678) 354-9470

★ Japan Headquarters
577-1 Obane, Shimizu-ward, Shizuoka-city, Shizuoka-pref.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”